Details for New Drug Application (NDA): 204921
✉ Email this page to a colleague
The generic ingredient in LACOSAMIDE is lacosamide. There are twenty-two drug master file entries for this compound. Fifty-six suppliers are listed for this compound. Additional details are available on the lacosamide profile page.
Summary for 204921
| Tradename: | LACOSAMIDE |
| Applicant: | Msn Labs Pvt Ltd |
| Ingredient: | lacosamide |
| Patents: | 0 |
Pharmacology for NDA: 204921
| Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Suppliers and Packaging for NDA: 204921
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LACOSAMIDE | lacosamide | TABLET;ORAL | 204921 | ANDA | Golden State Medical Supply, Inc. | 51407-721 | 51407-721-60 | 60 TABLET, FILM COATED in 1 BOTTLE (51407-721-60) |
| LACOSAMIDE | lacosamide | TABLET;ORAL | 204921 | ANDA | Golden State Medical Supply, Inc. | 51407-722 | 51407-722-60 | 60 TABLET, FILM COATED in 1 BOTTLE (51407-722-60) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 50MG | ||||
| Approval Date: | Mar 17, 2022 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 100MG | ||||
| Approval Date: | Mar 17, 2022 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 150MG | ||||
| Approval Date: | Mar 17, 2022 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
